NLSP - NLS Pharmaceutics AG

NLS Pharmaceutics AG, a biopharmaceutical company, is dedicated to the discovery and development of drug therapies to treat rare and complex disorders of the central nervous system. The company is headquartered in Stans, Switzerland.

52W High

$6.97

52W Low

$1.30

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.15

Valuation

As of 2024-09-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.02

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

4.84

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

32.46%

Institutions (25–75% balanced)

9.81%

Shares Outstanding

4,908,000

Float

1,687,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2024-09-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-2.63

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-8.63%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0692

-0.0812

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025